-
Mashup Score: 0
LONDON — Longitudinal serum alanine aminotransferase trajectories remained stable over time among a subset of patients with nonalcoholic fatty liver disease, according to research presented at the International Liver Congress. In a Healio exclusive interview, Arun J. Sanyal, MBBS, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, interim chair of the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 1Bulevirtide Reduces Hepatitis D Viral Load - 2 year(s) ago
Data from an ongoing study in patients with compensated cirrhosis and clinically significant portal hypertension have raised hope for an emerging treatment option in this rare, deadly disease.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Finding HBV ‘cure’ may mean going ‘back to the drawing board’ - 2 year(s) ago
Development of new HBV drugs looks more complicated than initially expected, and it’s time to refine and refocus goals, according to one researcher.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis. At the 2022 International Liver Congress, Terns conducted five oral and poster presentations on data from three programs, including TERN-501, which recently was evaluated in the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0
LONDON — Lower fatigue scores at baseline correlated with adverse clinical events among patients with advanced nonalcoholic steatohepatitis, according to research presented at the International Liver Congress.“Fatigue is very common in patients with NAFLD. In other diseases, fatigue is associated with adverse outcomes, including higher mortality,” Zobair M. Younossi, MD, MPH,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 4HBV Cure Going Back to the Drawing Board, Researchers Say - 2 year(s) ago
Findings presented at ILC 2022 in London revealed a cure for hepatitis B will not be easily achieved with the drugs currently in development.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
LONDON — Cirrhosis severity, infections and mortality outcomes were worse for patients in low to middle-income countries, due in part to poor access to liver transplant and ICU facilities, according to data presented here. “We have health care disparities as well as differing populations and diseases that cause cirrhosis around the world,” Jasmohan S. Bajaj, MD, associate
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 1
LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress. “The primary and key secondary endpoints from the study were achieved,” Stephen Harrison, MD, medical director for Pinnacle Clinical Research in San Antonio and visiting
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 1Statins in NAFLD: Taking a closer look at benefits - 2 year(s) ago
Statins could have multiple benefits in NAFLD, but there has been little insight into how they may be exerting such effects.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis. At the 2022 International Liver Congress, Terns conducted five oral and poster presentations on data from three programs, including TERN-501, which recently was evaluated in the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
Longitudinal serum alanine aminotransferase trajectories remained stable over time among a subset of patients with #NAFLD, according to research presented at #ILC2022 @EASLnews #MedTwitter #Hepatology #GITwitter https://t.co/56cKigP69D